Maze Therapeutics GAAP EPS of -$0.79
We haven't written up this one. Seeking Alpha News has the full story — the link below goes straight to it.
More in Finance & Markets
Stock Market Sell-Off: Meet the Unstoppable Vanguard ETF Obliterating the S&P 500 in 2026
Key PointsInvestors are trimming their exposure to artificial intelligence (AI) stocks amid worries about the sustainability of the infrastructure spending boom, and it's weighing on the S&P 500.
Why Bloom Energy Stock Slumped 26.6% in October, and Why the Pullback is a Buying Opportunity
Hyperscalers and data center operators are rushing for Bloom Energy's fuel cells.
- Bloom Energy's stock dropped 26.6% in October
- Project Jupiter delay and cash burn weighed on stock
- Record revenue and new contracts seen as buying opportunity
Hedge-Fund Founder Shah Fights 12-Year Danish Jail Sentence Over Cum-Ex Tax Scam
British hedge-fund trader Sanjay Shah returned to court in Denmark to try to overturn a 12-year prison sentence for orchestrating a billion-dollar tax scam.
Fed's Waller Supports Rate Hike in December
Federal Reserve Governor Christopher Waller said he supports an interest-rate hike in December, and warned that if inflation continues to accelerate he would support a half-percentage-point increase…
Higher US yields could push India towards export-led growth: SBICAPS
The research notes that India’s economic fundamentals remain relatively stable, supported by anchored inflation, gradual fiscal consolidation and an improving sovereign credit profile